Science & TechnologyHealth
News 19 of 22

SCTIMST Unveils Chitra Core Stent: 30-40% Less Metal, Reduces Restenosis & Thrombosis

Target:UPSC GS-IIIMPSCSSC GATeachingPrelims HighMains MediumStatic GK Link
15 Aug 2026
~2 min
Source: The Hindu
Key Data:30-40% less metalCDSCO license December 2025MoU 2024Aegis Graham Bell Awards 2024
Bodies:SCTIMSTCDSCOInvasive Technologies Pvt LtdDepartment of Science and Technology
Practice MCQs from today's news ▸
What This Article Covers

1.SCTIMST unveils 'Chitra Core', its first fully indigenous coronary stent, a Make in India milestone.

2.Chitra Core features a patented design with 30-40% less metal content to minimize vessel damage and reduce restenosis and late-stage thrombosis.

3.A second stent, 'Chitra TiN' (polymer-free, TiN-coated), is ready for pre-clinical evaluations for a global launch.

The Big Picture
Prelims · HighMains · Medium

SCTIMST has launched 'Chitra Core', a fully indigenous coronary stent with a patented design that uses 30-40% less metal than conventional stents, aiming to reduce complications like restenosis and thrombosis. A second stent, 'Chitra TiN' with a titanium nitride coating, is ready for global pre-clinical trials.

Exam Lens

Quick Exam Facts From News

OrganizationSCTIMST (Sree Chitra Tirunal Institute for Medical Sciences and Technology)
Stent Name 1Chitra Core (drug-eluting, polymer-coated)
Stent Name 2Chitra TiN (polymer-free, TiN-coated)
Key Feature30-40% less metal content than conventional stents
Regulatory LicenseCDSCO license secured in December 2025
AwardChitra TiN selected among top 3 innovations at Aegis Graham Bell Awards 2024

1-Minute Revision

  • ›Organization: SCTIMST (Sree Chitra Tirunal Institute for Medical Sciences and Technology)
  • ›Stent Name 1: Chitra Core (drug-eluting, polymer-coated)
  • ›Target this Data: 30-40% less metal content in Chitra Core stent.
  • ›Target this Nodal Body: SCTIMST (Sree Chitra Tirunal Institute for Medical Sciences and Technology) – an autonomous institute under the Department of Science and Technology.
  • ›Target this Legal Point: CDSCO license for manufacturing obtained in December 2025.

Mastered this topic? Test your knowledge with a full MCQ quiz.

Practice exam-style questions, track your score, and strengthen your recall.

Q1Static LinkageEasy

Which institute developed the Chitra Core coronary stent?

Q2Statement-basedHard

Consider the following statements regarding the Chitra Core stent:

1. It is a polymer-coated Everolimus drug-eluting stent.

2. It has 50% less metal content than conventional stents.

3. The design technology was transferred to Invasive Technologies Pvt Ltd under a MoU in 2024.

Which of the statements given above is/are correct?

Q3Data-centricMedium

By what percentage does the Chitra Core stent reduce metal content compared to conventional stents?

Q4Application/ImpactMedium

What is the primary advantage of the titanium nitride (TiN) coating used in the Chitra TiN stent?

All 15 MCQs ▸
You finished this topic
Explore Related Topics
Related Current Affairs
Science & Tech Current Affairs

India Gets First Disease-Modifying Alzheimer's Drug Leqembi After CDSCO Nod

Eisai's Leqembi (lecanemab), India's first disease-modifying therapy for early Alzheimer's, has been launched after CDSCO approval. This marks a shift from symptomatic to disease-modifying treatment, but challenges of early diagnosis, biomarker infrastructure, and affordability remain significant.

Science & Tech Current Affairs

CSIR-IICT Develops IND-Ready Phytopharmaceutical from Gymnema sylvestre for Diabetic Foot Ulcers

CSIR-IICT has developed a phytopharmaceutical from the medicinal plant Gymnema sylvestre for diabetic foot ulcers, a major complication of diabetes. The technology has been transferred to Mumbai-based Viridis Biopharma for clinical development and regulatory approvals, including CDSCO and USFDA. This marks a significant step in India's evidence-based botanical drug discovery and academia-industry collaboration.

Health & Education Current Affairs

WHO's IARC Classifies Hydrochlorothiazide, Voriconazole, Tacrolimus as Group 1 Carcinogens

Three widely used medicines for hypertension, fungal infections, and transplant rejection have been classified as Group 1 carcinogens by WHO's IARC. Patients are warned not to discontinue treatment without consulting doctors, as the classification identifies hazard, not real-world risk at prescribed doses.

Science & Tech Current Affairs

Narayana Health Reports Success in Haplo-Cord Transplant for Thalassaemia & Dual-Target CAR-T for Brain Cancer

Doctors at Narayana Health, West Bengal, have successfully treated a 7-year-old thalassaemia patient using a Haplo-cord transplant and a 62-year-old brain cancer patient with dual-target CAR T-cell therapy. These breakthroughs highlight India's growing capability in advanced cell-based therapies and are landmark achievements in treating previously challenging conditions.

Science & Tech Current Affairs

RK-251: India's ROS-Activated Smart Cancer Drug Could Transform Chemotherapy

RK-251 is a novel 'smart' cancer drug developed by Indian researchers that activates only inside cancer cells using high reactive oxygen species (ROS) levels, potentially reducing chemotherapy side effects. This marks a significant advancement in targeted cancer therapy and is a key topic for UPSC Science & Technology.

Science & Tech Current Affairs

Proposed Patient Data Collective (PDC) Model for Rare Diseases in India Inspired by Amul Cooperative

A new proposal suggests creating a Patient Data Collective (PDC) for rare diseases in India, modeled on the Amul dairy cooperative. This collective would pool patient data to accelerate drug discovery and clinical trials, addressing the challenge of small patient populations for rare diseases.

Science & Tech Current Affairs

IISc Bengaluru Discovers Cow Enzyme CRhAB Effective Against Drug-Resistant Biofilm Bacteria Klebsiella & Acinetobacter

IISc Bengaluru has discovered a new cow enzyme (CRhAB) that breaks down biofilms of two major drug-resistant bacteria (Klebsiella pneumoniae & Acinetobacter baumannii) found in hospitals. This breakthrough, published in Nature, offers a potential new treatment for chronic wound infections and diabetic foot ulcers.

Science & Tech Current Affairs

Telangana Proposes 6-Month Robotic Surgery Training for PG Medicos, NMC Nod Awaited

Telangana plans to make six months of robotic surgery training mandatory for postgraduate medical students, aiming to build a state-wide skilled workforce and expand advanced surgical procedures to district-level government hospitals. The proposal requires approval from the National Medical Commission (NMC).